MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.35
-0.42
-6.20%
Closed 19:57 09/20 EDT
OPEN
6.50
PREV CLOSE
6.77
HIGH
6.59
LOW
6.28
VOLUME
389.04K
TURNOVER
--
52 WEEK HIGH
7.73
52 WEEK LOW
1.250
MARKET CAP
377.70M
P/E (TTM)
-14.7263
1D
5D
1M
3M
1Y
5Y
What Type Of Shareholders Own The Most Number of Clearside Biomedical, Inc. (NASDAQ:CLSD) Shares?
A look at the shareholders of Clearside Biomedical, Inc. ( NASDAQ:CLSD ) can tell us which group is most powerful...
Simply Wall St. · 6d ago
Clearside Biomedical Expands XIPERE License Agreement With Arctic Vision To Include Australia, New Zealand, India And ASEAN Countries
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced
Benzinga · 09/09 11:10
Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries
– Increasing Global Awareness of Innovative Suprachoroidal Injection Platform –ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that ...
GlobeNewswire · 09/09 11:05
Clearside Biomedical Expands Xipere License Deal With Arctic Vision
MT Newswires · 09/09 10:13
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India
/PRNewswire/ -- Arctic Vision, a -based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to...
PR Newswire - PRF · 08/16 00:00
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 8.33% and 5.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 21:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSD. Analyze the recent business situations of Clearside through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSD stock price target is 11.60 with a high estimate of 18.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 23.07M
% Owned: 38.78%
Shares Outstanding: 59.48M
TypeInstitutionsShares
Increased
13
1.35M
New
10
2.85M
Decreased
15
1.89M
Sold Out
9
383.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
William Humphries
President/Chief Executive Officer/Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Other
Thomas Ciulla
Independent Director
Richard Croarkin
Independent Director
Jeffrey Edwards
Independent Director
Nancy Hutson
Independent Director
Christy Shaffer
Independent Director
Clay Thorp
No Data
  • All
  • Financials
  • Insiders
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.